Navigation Links
Pharmacopeia Acquires Selective Androgen Receptor Modulator ('SARM') Program from Bristol-Myers Squibb
Date:10/15/2007

d conditions."

In consideration for the SARM program license, Pharmacopeia will apply a portion of its medicinal chemistry resources to an unrelated Bristol-Myers Squibb discovery program for up to three years and pay Bristol-Myers Squibb milestone payments associated with submission and approval of a therapeutic product for marketing and a stepped royalty on net sales of therapeutic SARM products, if any, resulting from the SARM development program.

Pharmacopeia will hold a conference call today, October 15, beginning at 8:30 a.m. Eastern Time to discuss this addition to its clinical portfolio. Forward-looking and material information may be discussed on this conference call.

Date: October 15, 2007

Time: 8:30 a.m. EDT

Domestic Callers: (877) 879-6174

International Callers: (719) 325-4810

Confirmation Code: 3655914

Name of Conference: Pharmacopeia

Webcast information can be accessed by visiting http://www.pharmacopeia.com

A replay of the conference call can be accessed by dialing toll-free (888) 203-1112 in the U.S., or (719) 457-0820 outside the U.S. The access code for the replay is 3655914. A replay of the webcast will also be accessible on Pharmacopeia's website on the "Investors" page at http://www.pharmacopeia.com. The replays will be available for two weeks.

ABOUT PHARMACOPEIA

Pharmacopeia is a clinical development stage biopharmaceutical company dedicated to discovering and developing novel small molecule therapeutics to address significant medical needs. The company has a broad portfolio of clinical and preclinical candidates under development internally or with partners including seven clinical compounds in Phase 2 or Phase 1 development addressing hypertension, diabetic nephropathy, muscle wasting, inflammation and respiratory disease. The company is leveraging its fully int
'/>"/>

SOURCE Pharmacopeia
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related medicine news :

1. Ossur Acquires the U.S. Orthopaedics Company
2. Stem of Hope: Stem Cell Research Acquires a Brittle Star As A model
3. Pfizer Acquires Worldwide Rights For New Overactive Bladder Drug
4. Premier Army Hospital Acquires PET-CT Scanner
5. Wockhardt acquires Protinex, Farex brands from Netherland Co
6. Indoco Remedies Acquires La Nova Chem
7. Ranbaxy Acquires Glaxosmithklines Generic Unit in Spain
8. AIIMS Acquires Four-Armed Robot to Assist in Surgeries
9. Apollos Global Arm Acquires US-based Firm
10. ‘Obesity’ Acquires Permanent Resident Status in the US
11. Indias Wockhardt Acquires Irish Firm
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/5/2008)...tic children whose parents have high expectations ...kely to have symptoms than other children dealing ...dren also are more likely to use asthma controller...for taking medicine and if their parents clearly u... The study, which appears in the Oct. 2008 issue o...
(Date:10/3/2008)...ding is beneficial. But can it help kids lose weig...terature on obese adolescents, researchers at Duke...ight type of novel may make a difference. , The ...who were already in a comprehensive weight loss pr... Rescue (Beacon Street Press). It was carefully cr...
(Date:10/3/2008)... Inc. Magazine recently included,Connolly Consulti...ng,private companies in the country. The list is t...egment of the economy -- America,s,independent-min...es,represent the backbone of the U.S. economy., (...3/NY36880LOGO ), Connolly Consulting,s consisten...
(Date:10/3/2008)...idents to Eat Right, Move More and ...t. 3 /PRNewswire/ -- The last decade can be define...hich seem to go in and out,of fashion like shoulde...en,slim. Two out of three Americans -- including 2...weight or obese., A new campaign crossing the cou...
Breaking Medicine News(10 mins):Health News:Children's asthma affected by parental expectations 2Health News:Duke researchers show reading can help obese kids lose weight 2Health News:Connolly Consulting Makes the 2008 Inc. Magazine's List of America's 5000 Fastest Growing Companies 2Health News:Message to Pennsylvania Residents: Forgo Fad Dieting and Join the Campaign for Healthy Weight 2Health News:Message to Pennsylvania Residents: Forgo Fad Dieting and Join the Campaign for Healthy Weight 3
...ms of 11 patients with the dreaded genetic conditi...been relieved after liver transplants//. This is t... Children's Hospital of Pittsburgh and the Clinic ... the study (ranging in age from 1-20) are alive an...
...entre of Excellence for Integrative Legume Researc...btain useable nitrogen from soil bacteria// in the...ied a number of compounds, which could potentially...rs. Without an adequate blood supply tumours stop ...
...us, the one that causes mononucleosis, may be a ca...lts with high levels of antibodies//, according to... appear later in June 2006 print issue of Archives... have long suspected that external factors may inf...
...the UK government, requiring work permit to be mad... them to work in the National Health Service// (NH... doctors. With the change in rule, about 4,000 In...e expected to be affected in addition to about 850...
Other Medicine News:Health News:Liver Transplants to the Rescue of Dreaded MSUD disease 2Health News:Compounds In Legume May Be Helpful In Treating Cancer 2Health News:Epstein-Barr Virus May Be May Be A Cause For Multiple Sclerosis 2
(Date:10/6/2008)... - Data Presented at ACG Annual Scientific Confer...nwood Pharmaceuticals,(formerly Microbia) today an...nical studies delineating the role that cyclic gua...ntestinal pain. These studies,demonstrate that cGM...of,intestinal hyperalgesia and desensitizes coloni...
(Date:10/6/2008)...lts from Phase 3b Studies with Durezol Dosed Prior...Sirion Therapeutics, Inc., a,privately held ophtha...today that Durezol(TM) (difluprednate ophthalmic e...zol, which was approved by the U.S. Food and,Drug ...ic corticosteroid,indicated for the treatment of i...
(Date:10/6/2008)...than 60 percent of moderate to severe patients ach... achieved endoscopic remission at Week 10,in data ...merican College,of Gastroenterology (ACG) Annual S...ire/ -- UCB today presented data from a,large, pro...t in Crohn,s,disease (CD) with a biologic compound...
(Date:10/6/2008)...LE, Oct. 6 /- Dendreon Corp... today, Monday, October 6, 2008 at 9:00 AM,ET (6:0...ysis of its IMPACT,(IMmunotherapy for Prostate Ade...cal trial of PROVENGE(R) (sipuleucel-T), the Compa... for the treatment of advanced prostate,cancer., ...
Breaking Medicine Technology:Ironwood and Collaborators Present Preclinical Data Demonstrating That Cyclic GMP Alleviates Intestinal Pain 2Ironwood and Collaborators Present Preclinical Data Demonstrating That Cyclic GMP Alleviates Intestinal Pain 3Video: Sirion Therapeutics Launches Durezol for Postoperative Ocular Inflammation and Pain 2Video: Sirion Therapeutics Launches Durezol for Postoperative Ocular Inflammation and Pain 3Video: Sirion Therapeutics Launches Durezol for Postoperative Ocular Inflammation and Pain 4Video: Sirion Therapeutics Launches Durezol for Postoperative Ocular Inflammation and Pain 5CIMZIA(R) (certolizumab pegol) Reduces Intestinal Lesions and Induces Endoscopic Improvement in Crohn's Patients 2CIMZIA(R) (certolizumab pegol) Reduces Intestinal Lesions and Induces Endoscopic Improvement in Crohn's Patients 3CIMZIA(R) (certolizumab pegol) Reduces Intestinal Lesions and Induces Endoscopic Improvement in Crohn's Patients 4CIMZIA(R) (certolizumab pegol) Reduces Intestinal Lesions and Induces Endoscopic Improvement in Crohn's Patients 5CIMZIA(R) (certolizumab pegol) Reduces Intestinal Lesions and Induces Endoscopic Improvement in Crohn's Patients 6CIMZIA(R) (certolizumab pegol) Reduces Intestinal Lesions and Induces Endoscopic Improvement in Crohn's Patients 7Dendreon to Hold a Conference Call Today at 9:00 AM ET to Provide an Update on Interim Results of Phase 3 PROVENGE IMPACT Trial 2Protein Tomography 28TM 29 Reveals Molecular Mode of Action of Humax EGFr Published in PNAS 1869 1Protein Tomography 28TM 29 Reveals Molecular Mode of Action of Humax EGFr Published in PNAS 1869 2Survey 3A Employers Have High Confidence They Can Control Health Care Costs With Proper Tools 17389 1Survey 3A Employers Have High Confidence They Can Control Health Care Costs With Proper Tools 17389 2Survey 3A Employers Have High Confidence They Can Control Health Care Costs With Proper Tools 17389 3TopoTarget Successfully Buys Back Full Control of Belinostat 4752 1TopoTarget Successfully Buys Back Full Control of Belinostat 4752 2TopoTarget Successfully Buys Back Full Control of Belinostat 4752 3TopoTarget Successfully Buys Back Full Control of Belinostat 4752 4TopoTarget Successfully Buys Back Full Control of Belinostat 4752 5TopoTarget Successfully Buys Back Full Control of Belinostat 4752 6TopoTarget Successfully Buys Back Full Control of Belinostat 4752 7Mannatech Launches Business in South Africa 17387 1Mannatech Launches Business in South Africa 17387 2Mannatech Launches Business in South Africa 17387 3
...Presentation Details Statistically Significant Cli...ent of Diabetic Neuropathy, CHICAGO, June 22, 2007...c. announced today the presentation of encouraging...) program at the,67th Scientific Sessions of the A...n an oral presentation entitled, "Improved,Neurolo...
... FOSTER CITY, Calif.--(BUSINESS WIRE)--June 25, 20...unced that Study 103, a,Phase III clinical trial e...iread(R) (tenofovir disoproxil fumarate or tenofov... hepatitis B virus,(HBV) infection, met its primar...non-inferior to the company,s once-daily antiviral...
Other Medicine Technology:Sangamo BioSciences Announces Presentation of Phase 1 ZFP,Therapeutic Data at American Diabetes Association Meeting 2Sangamo BioSciences Announces Presentation of Phase 1 ZFP,Therapeutic Data at American Diabetes Association Meeting 3Sangamo BioSciences Announces Presentation of Phase 1 ZFP,Therapeutic Data at American Diabetes Association Meeting 4Sangamo BioSciences Announces Presentation of Phase 1 ZFP,Therapeutic Data at American Diabetes Association Meeting 5Sangamo BioSciences Announces Presentation of Phase 1 ZFP,Therapeutic Data at American Diabetes Association Meeting 6Sangamo BioSciences Announces Presentation of Phase 1 ZFP,Therapeutic Data at American Diabetes Association Meeting 7Sangamo BioSciences Announces Presentation of Phase 1 ZFP,Therapeutic Data at American Diabetes Association Meeting 8Sangamo BioSciences Announces Presentation of Phase 1 ZFP,Therapeutic Data at American Diabetes Association Meeting 9Second Phase III Study Evaluating Gilead's Viread for the Treatment,of Chronic Hepatitis B Virus Meets Primary Endpoint 2Second Phase III Study Evaluating Gilead's Viread for the Treatment,of Chronic Hepatitis B Virus Meets Primary Endpoint 3Second Phase III Study Evaluating Gilead's Viread for the Treatment,of Chronic Hepatitis B Virus Meets Primary Endpoint 4Second Phase III Study Evaluating Gilead's Viread for the Treatment,of Chronic Hepatitis B Virus Meets Primary Endpoint 5Second Phase III Study Evaluating Gilead's Viread for the Treatment,of Chronic Hepatitis B Virus Meets Primary Endpoint 6
...rt SI inserter from Bausch & Lomb provides fingert...ned for one handed delivery of the IOL directly in...assured by planar delivery. Leading haptic is posi...bag without sweeping motion. No additional instrum...
...erex Ultra Q is the fundamental capsulotmy laser -...ergy delivery and provides 2855% less energy in ai... in contemporary systems. This technology elimina...educes the risk of IOL pitting. , , , Ultr...
Protects the eye during or after surgery or trauma. Clear window dressing. Protects the eye allowing the patient to see.
Product designed specifically for posteror segment surgical procedures. For dissection of vitreoretinal membrames using viscoelastic fluid. A high pressure luer lock tubing set is attached to cannula
Medicine Products: